Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis (2025)
https://pubmed.ncbi.nlm.nih.gov/39757202/

Clonorchis sinensis excretory/secretory proteins ameliorate inflammation in rheumatoid arthritis and ankylosing spondylitis (2025)
https://pubmed.ncbi.nlm.nih.gov/40038824/

A Pilot Study on the Anti-Inflammatory Effects of Tacrolimus in Ankylosing Spondylitis: Evidence from Human Samples and a Murine Model (2025)
https://pubmed.ncbi.nlm.nih.gov/40757951/

Current Concepts and Medical Management for Patients with Radiographic Axial Spondyloarthritis (2024)
https://pubmed.ncbi.nlm.nih.gov/39620565/

A potential role of protein extractions from Metagonimus yokogawai in amelionating inflammation in patients with ankylosing spondylitis (2024)
https://pubmed.ncbi.nlm.nih.gov/38369180/

Usenamine A: a potential therapeutic agent for rheumatoid arthritis and ankylosing spondylitis through its anti-inflammatory activity (2024)
https://pubmed.ncbi.nlm.nih.gov/39691400/

CCL20 inhibition for treating inflammation in ankylosing spondylitis (2023)
https://pubmed.ncbi.nlm.nih.gov/37279731/

Korean treatment recommendations for patients with axial spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/37476674/

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/37907743/

IL-6 activates pathologic Th17 cell via STAT 3 phosphorylation in inflammatory joint of Ankylosing Spondylitis (2022)
https://pubmed.ncbi.nlm.nih.gov/35780583/

The Epidemiology and Treatment of Ankylosing Spondylitis in Korea (2022)
https://pubmed.ncbi.nlm.nih.gov/37476425/

Clonorchis sinensis-Derived Protein Attenuates Inflammation and New Bone Formation in Ankylosing Spondylitis (2021)
https://pubmed.ncbi.nlm.nih.gov/33717104/

STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis (2021)
https://pubmed.ncbi.nlm.nih.gov/33237331/

Self-care recommendations for patients with rheumatic diseases during the COVID-19 pandemic (2020)
https://pubmed.ncbi.nlm.nih.gov/32488428/

Switching to biosimilars in the treatment of rheumatic diseases (2018)
https://pubmed.ncbi.nlm.nih.gov/29914272/

Expression of activation-induced cytidine deaminase splicing variants in patients with ankylosing spondylitis (2017)
https://pubmed.ncbi.nlm.nih.gov/28959900/

Developing a Risk-scoring Model for Ankylosing Spondylitis Based on a Combination of HLA-B27, Single-nucleotide Polymorphism, and Copy Number Variant Markers. (2016)
https://pubmed.ncbi.nlm.nih.gov/27909141/

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. (2016)
https://pubmed.ncbi.nlm.nih.gov/27101309/

An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population (2015)
https://pubmed.ncbi.nlm.nih.gov/26613595/

ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients (2015)
https://pubmed.ncbi.nlm.nih.gov/25917849/

Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis (2014)
https://pubmed.ncbi.nlm.nih.gov/25121767/

Genome-wide copy number variation analysis identifies deletion variants associated with ankylosing spondylitis (2014)
https://pubmed.ncbi.nlm.nih.gov/24692264/

Restoration of overexpressed variable heavy chain 2 transcripts with tumor necrosis factor inhibitors in ankylosing spondylitis (2014)
https://pubmed.ncbi.nlm.nih.gov/24585525/

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci (2013)
https://pubmed.ncbi.nlm.nih.gov/23749187/